Charles Schwab’s Amneal Pharmaceuticals AMRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $37.2M | Sell |
2,147,450
-36,711
| -2% | -$503K | ﹤0.01% | 1441 |
|
|
2026
Q1 | $27.1M | Buy |
2,184,161
+39,690
| +2% | +$533K | ﹤0.01% | 1556 |
|
|
2025
Q4 | $27M | Buy |
2,144,471
+61,657
| +3% | +$705K | ﹤0.01% | 1560 |
|
|
2025
Q3 | $20.8M | Buy |
2,082,814
+260,492
| +14% | +$2.34M | ﹤0.01% | 1710 |
|
|
2025
Q2 | $14.7M | Buy |
1,822,322
+54,728
| +3% | +$413K | ﹤0.01% | 1827 |
|
|
2025
Q1 | $14.8M | Buy |
1,767,594
+227,660
| +15% | +$1.9M | ﹤0.01% | 1775 |
|
|
2024
Q4 | $12.2M | Buy |
1,539,934
+135,051
| +10% | +$1.13M | ﹤0.01% | 1929 |
|
|
2024
Q3 | $11.7M | Buy |
1,404,883
+202,863
| +17% | +$1.59M | ﹤0.01% | 1954 |
|
|
2024
Q2 | $7.63M | Sell |
1,202,020
-28,314
| -2% | -$180K | ﹤0.01% | 2163 |
|
|
2024
Q1 | $7.46M | Sell |
1,230,334
-99,174
| -7% | -$559K | ﹤0.01% | 2130 |
|
|
2023
Q4 | $8.07M | Buy |
1,329,508
+26,875
| +2% | +$120K | ﹤0.01% | 2102 |
|
|
2023
Q3 | $5.5M | Buy |
1,302,633
+47,599
| +4% | +$178K | ﹤0.01% | 2208 |
|
|
2023
Q2 | $3.89M | Buy |
1,255,034
+96,631
| +8% | +$206K | ﹤0.01% | 2331 |
|
|
2023
Q1 | $1.61M | Sell |
1,158,403
-38,138
| -3% | -$75.9K | ﹤0.01% | 2580 |
|
|
2022
Q4 | $2.38M | Buy |
1,196,541
+6,945
| +0.6% | +$15.6K | ﹤0.01% | 2512 |
|
|
2022
Q3 | $2.4M | Buy |
1,189,596
+23,282
| +2% | +$65.2K | ﹤0.01% | 2532 |
|
|
2022
Q2 | $3.71M | Sell |
1,166,314
-14,332
| -1% | -$51.9K | ﹤0.01% | 2313 |
|
|
2022
Q1 | $4.92M | Buy |
1,180,646
+19,009
| +2% | +$84.2K | ﹤0.01% | 2284 |
|
|
2021
Q4 | $5.57M | Buy |
1,161,637
+15,374
| +1% | +$76.6K | ﹤0.01% | 2299 |
|
|
2021
Q3 | $6.12M | Buy |
1,146,263
+49,813
| +5% | +$251K | ﹤0.01% | 2272 |
|
|
2021
Q2 | $5.61M | Buy |
1,096,450
+210,536
| +24% | +$1.2M | ﹤0.01% | 2292 |
|
|
2021
Q1 | $5.96M | Buy |
885,914
+157,112
| +22% | +$871K | ﹤0.01% | 2208 |
|
|
2020
Q4 | $3.33M | Buy |
728,802
+701
| +0.1% | +$3.11K | ﹤0.01% | 2414 |
|
|
2020
Q3 | $2.83M | Sell |
728,101
-26,915
| -4% | -$115K | ﹤0.01% | 2366 |
|
|
2020
Q2 | $3.59M | Buy |
755,016
+48,210
| +7% | +$199K | ﹤0.01% | 2184 |
|
|
2020
Q1 | $2.46M | Buy |
706,806
+15,068
| +2% | +$63.8K | ﹤0.01% | 2189 |
|
|
2019
Q4 | $3.33M | Buy |
691,738
+129,741
| +23% | +$451K | ﹤0.01% | 2223 |
|
|
2019
Q3 | $1.63M | Sell |
561,997
-143,660
| -20% | -$501K | ﹤0.01% | 2451 |
|
|
2019
Q2 | $5.06M | Buy |
705,657
+33,072
| +5% | +$338K | ﹤0.01% | 1967 |
|
|
2019
Q1 | $9.53M | Buy |
672,585
+81,666
| +14% | +$1.08M | 0.01% | 1631 |
|
|
2018
Q4 | $8M | Buy |
590,919
+33,486
| +6% | +$603K | 0.01% | 1607 |
|
|
2018
Q3 | $12.4M | Buy |
557,433
+141,429
| +34% | +$2.98M | 0.01% | 1487 |
|
|
2018
Q2 | $6.83M | Buy |
+416,004
| New | +$7.3M | 0.01% | 1841 |
|
Other funds holding AMRX
TGA
RCMNY
Charles Schwab's AMRX Position: Q2 2026 in Review
Charles Schwab reduced its Amneal Pharmaceuticals (AMRX) stake by 1.7% in Q2 2026, selling an estimated $503K and leaving 2,147,450 shares worth $37.2M. The position accounts for ﹤0.01% of the portfolio, ranked #1441.
Charles Schwab first reported a position in AMRX in Q2 2018 and has held it in 33 quarters since. 306 funds tracked by Wall St. Rank hold AMRX as of Q2 2026.
- Charles Schwab held 2,147,450 shares of Amneal Pharmaceuticals worth $37.2M as of Q2 2026.
- Charles Schwab sold 36,711 Amneal Pharmaceuticals shares in Q2 2026, an estimated $503K.
- Amneal Pharmaceuticals made up ﹤0.01% of Charles Schwab's portfolio in Q2 2026, its #1441 holding.
- Charles Schwab first reported a position in Amneal Pharmaceuticals in Q2 2018 and has held it in 33 quarters since.
- 306 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q2 2026.
Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.